Harvard Bioscience, Inc. announced a CEO succession plan, with John Duke set to assume the role of President & CEO, effective July 28, 2025. This follows the planned retirement of Jim Green, who served as President, CEO, and Chairman for over six years as CEO and eight years as Chairman.
Mr. Duke, already a member of the Board of Directors, previously served as Chief Executive Officer of Plastic Molding Technology, where he achieved approximately 20% annual revenue growth. His background also includes over 20 years at Corning Incorporated, with ten years in its Life Sciences division, providing extensive industry experience.
The company also announced the appointment of Rob Gagnon and Seth Benson to the Board of Directors, effective July 16, 2025. Mr. Gagnon, a former CFO of Harvard Bioscience, brings over 20 years of global finance operations experience in life sciences, while Mr. Benson offers over 20 years of leadership in finance, technology, and operations, including significant time in life science tools. Additionally, the company expects Q2 2025 revenue to be $20.4 million and reiterated its gross margin guidance of 55% to 57% for the quarter.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.